XML 81 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Stock Options Issued and Outstanding Activities (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Number of Stock Options, Outstanding 5,504,383 2,565,377  
Weighted Average Exercise Price, Outstanding $ 2.00 $ 3.14  
Remaining Contractual Term (Years) 8 years 1 month 6 days [1] 8 years 6 months 8 years 3 months 18 days
Intrinsic Value, Outstanding [2] $ 765  
Number of Stock Options, Granted [3] 3,733,000 3,618,000  
Weighted Average Exercise Price, Granted [3] $ 1.21 $ 1.32  
Number of Stock Options, Exercised (3,333)  
Weighted Average Exercise Price, Exercised $ 1.31  
Number of Stock Options, Forfeited (587,292) (678,994)  
Weighted Average Exercise Price, Forfeited $ 1.59 $ 2.75  
Number of Stock Options, Outstanding 8,646,758 [1] 5,504,383 2,565,377
Weighted Average Exercise Price, Outstanding $ 1.68 [1] $ 2.00 $ 3.14
Intrinsic Value, Outstanding [2] $ 199 [1] $ 765
Number of Stock Options, Vested and exercisable stock options 4,918,408    
Weighted Average Exercise Price, Vested and exercisable stock options $ 2.02    
Remaining Contractual Term (Years), Vested and exercisable stock options 7 years 6 months    
Intrinsic Value, Vested and exercisable stock options $ 198    
[1] The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of December 31, 2024 and 2023.
[2] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of December 31, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
[3] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.